Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Misako Nagasaka

Showing results (1-10 of 207) with videos related to

Pageof 21
Sort By:
Lung Cancer (Auckland, N.Z.)|December 9, 2021
Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung CancerDanielle Brazel, Misako Nagasaka
Lung Cancer (Auckland, N.Z.)|May 26, 2022
Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLCDanielle Brazel, Misako Nagasaka
Oral Oncology|January 25, 2021
Forget me not - Incorporating standard chemotherapy in an exciting era of clinical trialsAlexis Nguyen, Misako Nagasaka
Expert Review of Respiratory Medicine|February 18, 2025
Amivantamab plus lazertinib vs. osimertinib in first-line <i>EGFR</i>-mutant advanced non-small cell lung cancerNazmul Hasan, Misako Nagasaka
Lung Cancer (Auckland, N.Z.)|April 18, 2024
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?Danielle Brazel, Misako Nagasaka
Drug Design, Development and Therapy|December 10, 2024
Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in TherapyBrian Warnecke, Misako Nagasaka
Cancer Management and Research|July 17, 2023
Spotlight on Cemiplimab-rwlc in the Treatment of Non-Small Cell Lung Cancer (NSCLC): Focus on Patient Selection and ConsiderationsJeffrey Ahn, Misako Nagasaka
Cancer Metastasis Reviews|June 21, 2022
PrefaceMisako Nagasaka, Grace Chen
Cancer Treatment Reviews|April 18, 2024
Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancerChristopher Grant, Misako Nagasaka
Translational Lung Cancer Research|July 8, 2024
The APPLE trial in the evolving landscape of ctDNA monitoringDanielle Brazel, Misako Nagasaka
Pageof 21

Showing results (1-10 of 207) with videos related to

Sort By:
Pageof 21
Lung Cancer (Auckland, N.Z.)|December 9, 2021
Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung CancerDanielle Brazel, Misako Nagasaka
Lung Cancer (Auckland, N.Z.)|May 26, 2022
Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLCDanielle Brazel, Misako Nagasaka
Oral Oncology|January 25, 2021
Forget me not - Incorporating standard chemotherapy in an exciting era of clinical trialsAlexis Nguyen, Misako Nagasaka
Expert Review of Respiratory Medicine|February 18, 2025
Amivantamab plus lazertinib vs. osimertinib in first-line <i>EGFR</i>-mutant advanced non-small cell lung cancerNazmul Hasan, Misako Nagasaka
Lung Cancer (Auckland, N.Z.)|April 18, 2024
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?Danielle Brazel, Misako Nagasaka
Drug Design, Development and Therapy|December 10, 2024
Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in TherapyBrian Warnecke, Misako Nagasaka
Cancer Management and Research|July 17, 2023
Spotlight on Cemiplimab-rwlc in the Treatment of Non-Small Cell Lung Cancer (NSCLC): Focus on Patient Selection and ConsiderationsJeffrey Ahn, Misako Nagasaka
Cancer Metastasis Reviews|June 21, 2022
PrefaceMisako Nagasaka, Grace Chen
Cancer Treatment Reviews|April 18, 2024
Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancerChristopher Grant, Misako Nagasaka
Translational Lung Cancer Research|July 8, 2024
The APPLE trial in the evolving landscape of ctDNA monitoringDanielle Brazel, Misako Nagasaka
Pageof 21